Back to Blog

Letrozole for Endometrial Preparation: When It May Be Considered

Dr. Senai Aksoy · · 8 min read
Medically reviewed on 11 August 2026 - Dr. Senai Aksoy
Woman reviewing a fertility-cycle calendar at home while considering treatment options

Key Takeaways

Letrozole is established mainly as an ovulation-induction medicine, especially for anovulatory PCOS. In frozen embryo transfer, a letrozole-stimulated cycle may be a reasonable alternative for some patients with irregular or absent ovulation, but current evidence is low-certainty and does not establish a universal implantation benefit.

Key evidence: 2023 International PCOS Guideline (ASRM) 2025 letrozole FET systematic review and meta-analysis Cochrane review of FET endometrial preparation

Frozen embryo transfer with letrozole

Frozen embryo transfer with letrozole

What letrozole actually does

Letrozole temporarily blocks aromatase, lowering estrogen early in the cycle. The pituitary may then release more follicle-stimulating hormone (FSH), helping a follicle grow and ovulate. In a stimulated FET cycle, that ovulation can create the body’s own estrogen, progesterone and corpus luteum. This differs from a programmed cycle, in which estrogen and progesterone are prescribed.

That mechanism explains why the option is biologically plausible. It does not prove that the endometrium will be more receptive or that live birth will be more likely.

Where the evidence is clearest

Anovulatory PCOS or irregular ovulation

Letrozole is a first-line pharmacological ovulation-induction treatment for infertile anovulatory adults with PCOS when there is no other infertility factor that changes the plan. The 2023 International PCOS Guideline (ASRM) supports that use. The recommendation is about restoring ovulation—not about proving a separate implantation-enhancing effect in FET.

A 2025 systematic review and meta-analysis of PCOS or oligo-anovulatory FET included 15 observational studies and two randomized trials. It found a modest apparent live-birth advantage, but every outcome was judged low-certainty; the randomized trial reporting live birth did not confirm an advantage. The Human Reproduction Update review therefore supports “a possible alternative,” not “a proven better protocol.”

People who already ovulate regularly

Evidence is less persuasive when ovulation is already regular. Trials comparing letrozole-stimulated and hormone-replacement FET have generally found similar pregnancy outcomes or no clear superiority. A randomized trial in women with regular ovulatory cycles found no significant difference in pregnancy outcomes. A molecular marker or endometrial-thickness change is an intermediate finding; it is not the same as a higher live-birth rate.

For a patient who already ovulates, a natural or modified-natural FET cycle is also a separate option—not simply a choice between letrozole and a programmed cycle. In a 2026 multicentre randomized trial of 4,376 ovulatory women, natural and programmed cycles produced similar healthy live-birth rates; pre-eclampsia was lower with natural ovulation, but cycle cancellation was more common. The BMJ trial was not a letrozole trial, so it informs the wider protocol discussion rather than proving that letrozole is preferable.

What can change the choice in practice

Dr. Aksoy’s clinical input places the emphasis on a practical question: can the patient reliably develop one dominant follicle and a corpus luteum with letrozole? A previous letrozole response, reliable ultrasound and hormone monitoring, and a clinical reason to avoid a corpus-luteum-free programmed cycle may favor stimulation. The 2025 review also found lower odds of hypertensive disorders with letrozole-stimulated FET, although the certainty of that evidence was low. Thrombotic risk is a patient-specific clinical consideration here; this review evaluated hypertensive disorders, not proof that letrozole prevents thrombosis. Human Reproduction Update

Current randomized evidence does not show a consistent live-birth advantage. A 420-participant trial found nearly identical live-birth rates, and a 2025 trial of 200 patients found no statistically significant difference in clinical pregnancy. The 2023 randomized trial and the 2025 randomized trial support treating letrozole as an individualized option rather than an automatic choice for every patient with PCOS. The 2023 trial also reported more gestational diabetes in the letrozole group (14.6% vs 5.6%) and a difference in singleton birth weight, so obstetric advantages should not be treated as settled. The 2025 meta-analysis found no overall difference in gestational diabetes, which makes the single-trial signal uncertain. The meta-analysis reported low-certainty evidence for this outcome. A multicentre 2025 randomized trial of 155 women with PCOS likewise found no significant difference in clinical pregnancy, live birth or reported obstetric outcomes between letrozole and programmed preparation. That trial supports the same cautious interpretation. A small 2026 randomized trial reported higher clinical and “successful pregnancy” counts with mild stimulation, but it included only 100 participants and did not establish a live-birth advantage. The 2026 trial should therefore be interpreted cautiously.

Letrozole may be a poor fit after inadequate follicular development or repeated cycle cancellation, repeated thin endometrium, uncontrolled multifollicular response, unreliable ovulation timing, marked hypogonadotropic or hypoestrogenic states, or when the patient cannot complete monitoring. A programmed cycle may be more practical when the transfer date must be scheduled precisely.

What the decision depends on

A clinician may consider:

The choice is not made from lining thickness alone. A thin lining, a cavity problem, embryo quality, or progesterone timing may require a different evaluation.

What a letrozole FET cycle involves

The exact plan varies. It usually means early-cycle medication, ultrasound monitoring of follicle growth and endometrium, confirmation and timing of ovulation, and carefully timed progesterone and embryo transfer. Some cycles are cancelled or changed if the follicle, lining or timing is not suitable.

This is why letrozole should not be treated as a self-directed add-on or as a substitute for investigating repeated implantation failure.

Safety and practical limits

Letrozole use for fertility is off-label in many countries. A pregnancy should be excluded before treatment; letrozole should not be taken during an established pregnancy. The ASRM guideline and the official DailyMed label describe these boundaries.

Short courses can still cause side effects such as headache, fatigue, dizziness or hot flushes. Your clinician should review other medicines, liver disease, ovarian response and the risk of multiple pregnancy. Do not start, stop or change the dose from an online protocol.

What it cannot fix

Letrozole cannot correct poor embryo quality, a uterine-cavity abnormality, hydrosalpinx, incorrectly timed progesterone exposure, or every cause of repeated implantation failure. It cannot guarantee implantation, pregnancy or live birth.

A practical way to frame the conversation

Ask your fertility team:

  1. Do I ovulate regularly, and is that confirmed?
  2. What problem are we trying to solve: ovulation, lining, scheduling, or a previous failed transfer?
  3. What evidence applies to my patient group?
  4. How will follicle growth, endometrium and progesterone timing be monitored?
  5. What would make us change or cancel the cycle?

The best protocol is the one that matches the actual problem, not the one with the most attractive mechanism.

FAQ

Is letrozole only for PCOS?

No. It is also used in selected ovulatory-disorder and FET protocols, but the strength of evidence differs by population.

Does letrozole make the lining receptive?

It may create a physiologic ovulatory cycle in some patients. That does not prove a higher live-birth chance.

Is it better than an estrogen-and-progesterone programmed cycle?

Not for everyone. In PCOS or oligo-anovulation it may be a viable alternative, but current evidence is low-certainty. In regularly ovulating patients, superiority is not established.

Can I take letrozole if I might already be pregnant?

No. Pregnancy should be excluded before treatment, and letrozole should not be taken during an established pregnancy.

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a founding member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

Instagram YouTube

The content has been created by Dr. Senai Aksoy and medically approved.